Mesoblast (MSB) Stock Price, Fundamentals & Analysis

What MSB does

Mesoblast (MSB) is a Healthcare sector stock in the Biotechnology industry, listed on the ASX and headquartered in Melbourne, Australia. The company develops regenerative medicine products based on mesenchymal lineage cells. Its pipeline includes remestemcel-L-rknd in Phase III trials for systemic inflammatory diseases such as steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease. It also has Remestemcel-L in Phase III for chronic heart failure and chronic low back pain due to degenerative disc disease, and Revascor for hypoplastic left heart syndrome. Additional candidates include MPC-300-IV for biologic refractory rheumatoid arthritis diabetic nephropathy, MPC-150-IM for chronic heart failure, Ryoncil for pediatric SR-aGVHD, and MPC-25-IC for acute myocardial infarction. With 108 employees, Mesoblast operates as a small-cap biotech firm.

Key numbers explained

• 2.16 AUD is the current share price, the amount you would pay for one share right now.
• -1.37% is the price change today, showing the intraday move relative to the previous close.
• 2,8 mld. AUD is the market capitalization, the total value of all outstanding shares.
• 19,1 is the forward P/E ratio, which divides the current price by expected future earnings; a lower figure can suggest lower growth expectations relative to peers.
• 0% is the dividend yield, meaning the company does not currently pay a cash dividend.
• 0% is the share of earnings paid out as dividends, confirming that earnings are retained rather than distributed.
• 0,82 is beta, a measure of volatility relative to the market; a value below 1 suggests lower sensitivity to market swings.
• 1,88 – 3,31 is the 52-week price range, showing the lowest and highest traded prices over the past year.
• -10,7% is the price change over the last 52 weeks, indicating the total return from one year ago to today.
• 120,25 mil. USD is trailing 12-month revenue, the total sales over the past twelve months.
• 390,7% is year-over-year revenue growth, reflecting a significant increase in sales on a percentage basis.
• -47,8% is the profit margin, showing that the company is currently operating at a loss relative to revenue.
• -33,3% is the operating margin, another measure of profitability before interest and taxes.
• -9,9% is the return on equity, indicating a negative return for shareholders on their invested capital.
• 22,4% is the debt-to-equity ratio, a leverage metric comparing borrowed funds to shareholder equity.
• 3,45 is the price-to-book ratio, comparing the market price to the book value of equity per share.

What to watch

Mesoblast's share price can be influenced by clinical trial readouts for its regenerative medicine pipeline, regulatory decisions on products such as remestemcel-L-rknd and Ryoncil, and broader movements in the ASX 200 index, of which it is a component. Investors often monitor upcoming catalysts such as the nextEarningsDate on 26 aug. 2026, as well as peer activity in Australian biotech names like Pro Medicus (PME), Telix Pharmaceuticals (TLX), Ryman Healthcare (RYM), Sigma Healthcare (SIG), Sonic Healthcare (SHL), Ansell (ANN), and Fisher & Paykel Healthcare (FPH). General factors include funding and partnership developments, cash burn relative to revenue growth, and the overall risk appetite for small-cap healthcare stocks.